Shares in Alcon, the eye care business being spun-off by Novartis, are expected to start trading on April 9 on the Swiss market and the New York Stock Exchange, the Swiss pharmaceuticals company said on Friday.
“Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange,” Novartis said in a statement, adding that Alcon would enter the SMI, Switzerland’s blue-chip stock index, on its first trading day.
Novartis said Alcon had secured debt financing of $3.5 billion, adding that Bank of America Merrill Lynch and UBS were advising Novartis on the transaction.
Under the distribution, each Novartis shareholder will receive one Alcon share for every five Novartis shares or American depositary receipts they hold at the close of business on April 8.
Alcon has said it plans to pay a dividend in 2020 and will focus on “bolt-on” acquisitions to help boost operating margins to the mid-20 percent range, from the high-teens now.
The business was bought from Nestle for $52 billion in 2011, as former Novartis Chairman Daniel Vasella sought to build the Swiss drug company into a European healthcare giant along the lines of U.S.-based Johnson & Johnson.
But Alcon became a trouble spot for Novartis, which had to make massive investments to reverse falling sales and losses.
Novartis Chief Executive Officer Vas Narasimhan decided to unload the business last year to focus on new drugs, not the surgical devices and contact lenses that Alcon makes.
By Riham Alkousaa and John Revill
Lonza will invest to expand its drug product manufacturing network in Switzerland. The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel. The expansion adds new capabilities to support clinical and commercial manufacturing and enhances existing drug product service offering in Basel and Visp.
Partial reprogramming of adult heart cells to a fetal-like state could help repair heart damage following cardiac injury or disease, scientists at the Max Planck Institute for Heart and Lung Research showed in mice.
When Merck’s women’s health spinoff Organon launched in June, it promised to listen to—and amplify—women’s voices on overlooked health concerns. Now, the company is getting specific. Organon hopes to ignite a conversation about an issue that affects 121 million women around the world every year.